HC Wainwright initiated coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) in a research note issued on Thursday,Benzinga reports. The firm set a “buy” rating and a $12.00 price target on the stock.
KAPA has been the topic of a number of other reports. Maxim Group assumed coverage on shares of Kairos Pharma in a research note on Thursday, March 27th. They issued a “buy” rating and a $4.00 price objective on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Kairos Pharma in a research report on Monday.
Check Out Our Latest Report on KAPA
Kairos Pharma Trading Down 0.2 %
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
See Also
- Five stocks we like better than Kairos Pharma
- Canadian Penny Stocks: Can They Make You Rich?
- Tesla Stock: What To Expect With Their Delivery Numbers Report
- Where to Find Earnings Call Transcripts
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
